These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23812645)

  • 1. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.
    Vauquelin G
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):949-62. PubMed ID: 23812645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2013 Apr; 168(8):1771-85. PubMed ID: 23330947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.
    Vauquelin G; Bricca G; Van Liefde I
    Fundam Clin Pharmacol; 2014 Oct; 28(5):530-43. PubMed ID: 24118041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.
    Vauquelin G; Hall D; Charlton SJ
    Br J Pharmacol; 2015 May; 172(9):2300-15. PubMed ID: 25537684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.
    Vauquelin G
    Br J Pharmacol; 2017 Dec; 174(23):4233-4246. PubMed ID: 28838028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.
    Vauquelin G
    Expert Opin Drug Discov; 2015 Oct; 10(10):1085-98. PubMed ID: 26165720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced fit versus conformational selection: From rate constants to fluxes… and back to rate constants.
    Vauquelin G; Maes D
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00847. PubMed ID: 34459109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.
    Bobrovnik SA
    J Mol Recognit; 2007; 20(4):253-62. PubMed ID: 17847051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of tether length in nonglycosidically linked bivalent ligands that target sites 2 and 1 of a Shiga-like toxin.
    Kitov PI; Shimizu H; Homans SW; Bundle DR
    J Am Chem Soc; 2003 Mar; 125(11):3284-94. PubMed ID: 12630884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.
    Vauquelin G; Van Liefde I; Swinney DC
    Br J Pharmacol; 2016 Apr; 173(8):1268-85. PubMed ID: 26808227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miscalculating Equilibrium Constants for Multivalent Protein Complexes: Site-Binding Concentration or Protein Molecular Concentration?
    Klakamp SL; Drake AW
    J Pharm Sci; 2021 Jul; 110(7):2585-2589. PubMed ID: 33831440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of ligand bivalency in interactions involving particulate receptors: equilibrium and kinetic studies with Sephadex-concanavalin A, butylagarose-phosphorylase b, and Fc receptor-IgG dimer interactions as model systems.
    Hogg PJ; Reilly PE; Winzor DJ
    Biochemistry; 1987 Apr; 26(7):1867-73. PubMed ID: 2439115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.
    Vauquelin G; Van Liefde I
    Expert Opin Drug Discov; 2012 Jul; 7(7):583-95. PubMed ID: 22650795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition in drug binding and … the race to equilibrium.
    Vauquelin G; Maes D
    Fundam Clin Pharmacol; 2023 Feb; 37(1):147-157. PubMed ID: 35981720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multivalency in the affinity chromatography of antibodies. Appendix: Derivation and evaluation of equations for independent bivalent interacting systems in quantitative affinity chromatography.
    Eilat D; Chaiken IM; McCormick WM
    Biochemistry; 1979 Mar; 18(5):790-5. PubMed ID: 420816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH
    Lensing CJ; Adank DN; Wilber SL; Freeman KT; Schnell SM; Speth RC; Zarth AT; Haskell-Luevano C
    ACS Chem Neurosci; 2017 Jun; 8(6):1262-1278. PubMed ID: 28128928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR-based screening methods for lead discovery.
    Vogtherr M; Fiebig K
    EXS; 2003; (93):183-202. PubMed ID: 12613177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical analysis of the footprinting experiment.
    Goodisman J; Dabrowiak JC
    J Biomol Struct Dyn; 1985 Feb; 2(5):967-79. PubMed ID: 2855783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural activation pathways from dynamic olfactory receptor-odorant interactions.
    Lai PC; Singer MS; Crasto CJ
    Chem Senses; 2005 Nov; 30(9):781-92. PubMed ID: 16243965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.
    Packeu A; Wennerberg M; Balendran A; Vauquelin G
    Br J Pharmacol; 2010 Nov; 161(6):1311-28. PubMed ID: 20946109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.